Identifying biomarkers for toxicity in malignant pleural mesothelioma patients treated with radiotherapy

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study focuses on malignant pleural mesothelioma (MPM), a type of cancer affecting the pleural layers surrounding the lungs. It aims to identify circulating biomarkers that can predict severe toxicity in patients undergoing high-dose radiotherapy combined with immune checkpoint inhibitors. By monitoring molecules involved in inflammation and oxidative stress, the study seeks to assess risk factors associated with pulmonary toxicity from these treatments. The goal is to improve patient safety and treatment outcomes by understanding the biological responses to radical radiation therapy.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Over 18 years of age;
* Ability to understand, accept and sign consent informed;
* Histological diagnosis of malignant pleural mesothelioma;
* Previous administration of chemotherapy;
* Previous non-radical surgical approach (diagnostic thoracoscopy or R1-R2 surgery);
* Subject eligible for or already treated with RT on hemithorax for radical purposes (50 Gy in fractions on hemithorax + possible boost 60 Gy on residual PET+)

Exclusion Criteria:

* Disease not histologically established
* Progression pattern not amenable to radiation treatment (ipsilateral or metastatic intrathoracic extensive disease);
* Metastatic patient at diagnosis.

Where it's running

• Centro di Riferimento Oncologico (CRO) di Aviano - IRCCS
  Aviano, Pordenone, Italy Recruiting

Study contacts

• Principal investigator: Alberto Revelant, MD — Centro di Riferimento Oncologico (CRO) di Aviano - IRCCS
• Study coordinator: Alberto Revelant, MD
• Email: alberto.revelant@cro.it
• Phone: 0434 659 159

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Evaluating TT-10 and TT-4 for advanced solid tumors

  This study is testing two new drugs, TT-10 and TT-4, to see if they are safe and effective for people with advanced solid tumors who haven't had success with other treatments.

  Recruiting at 2 sites Phase 1/2 Portage Biotech · Los Angeles, California and 1 other locations · NCT04969315

• Measuring treatment response in malignant pleural mesothelioma using breathprinting technology

  This study is testing if a special breath-sensing device can help track how well treatment is working for people with malignant pleural mesothelioma.

  Recruiting at 7 sites Memorial Sloan Kettering Cancer Center · Basking Ridge, New Jersey and 6 other locations · NCT06037941

• Combining a PD-L1 inhibitor and dendritic cell vaccination with chemotherapy for malignant pleural mesothelioma

  This study is testing a new treatment that combines a PD-L1 blocker and a special vaccine with chemotherapy to see if it helps people with a type of lung cancer called malignant pleural mesothelioma.

  Recruiting at 3 sites Phase 1/2 University Hospital, Antwerp · Edegem, Antwerp and 2 other locations · NCT05765084

• Proton therapy for treating malignant pleural mesothelioma

  This study is testing if proton therapy can help people with malignant pleural mesothelioma live longer and feel better compared to standard care.

  Recruiting at 24 sites University College, London · Eastbourne, East Sussex and 24 other locations · NCT05655078

• Innovative treatment combining photodynamic therapy and immunotherapy for malignant pleural mesothelioma

  This study is testing a new treatment that combines light therapy and immune therapy to see if it can help patients with advanced malignant pleural mesothelioma who haven't responded well to chemotherapy.

  Recruiting Phase 2 University Hospital, Lille · Lille · NCT04400539

• APG-2449 for advanced solid tumors

  This study is testing a new oral medication called APG-2449 to see how well it works and what the safe dosage is for people with advanced solid tumors like non-small cell lung cancer.

  Recruiting at 7 sites Phase 1 Ascentage Pharma Group Inc. · Beijing, Beijing Municipality and 8 other locations · NCT03917043

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.